BioXcel Therapeutics
BTAI
BTAI
30 hedge funds and large institutions have $770K invested in BioXcel Therapeutics in 2025 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
30
Holders Change
-18
Holders Change %
-37.5%
% of All Funds
0.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
10
Reduced
12
Closed
23
Calls
$17K
Puts
$4K
Net Calls
+$13K
Net Calls Change
+$18K
Top Buyers
| 1 |
M
Murchinson
Toronto,
Ontario, Canada
|
+$276K |
| 2 |
Goldman Sachs
New York
|
+$50.3K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$44.6K |
| 4 |
BPA
Beacon Pointe Advisors
Newport Beach,
California
|
+$38.3K |
| 5 |
VF
Virtu Financial
New York
|
+$19.8K |
Top Sellers
| 1 |
AC
Armistice Capital
New York
|
-$1.61M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$112K |
| 3 |
Millennium Management
New York
|
-$39.2K |
| 4 |
Renaissance Technologies
New York
|
-$29.1K |
| 5 |
State Street
Boston,
Massachusetts
|
-$28.8K |
